tirzepatide components Compound Tirzepatide - an overview |

Trends in Endocrinology & Metabolism, 28(5), 340-353

Patel RT, Gay JJ, Fagan KK, Eikenberg JD

Targeting these amino acid-driven metabolic circuits may offer novel therapeutic opportunities in fibrotic diseases such as IPF, where metabolic vulnerabilities can be exploited to disrupt fibroblast activation and excessive ECM remodeling

No regulatory guidance yet defines what biosimilarity means for an ADC like Kadcyla (ado-trastuzumab emtansine), where the drug-to-antibody ratio, linker chemistry, and released drug identity are all potential similarity endpoints in addition to the standard antibody characterization package